Lymphoma treatment: Targretin® (bexarotene)

SRI and the La Jolla Cancer Research Foundation (now the Sanford-Burnham Research Institute) collaborated on work that resulted in patent filings for the drug bexarotene, approved in 1999 by the Food and Drug Administration to treat cutaneous T-cell lymphoma—a rare disorder of the immune system where T-cells, a type of white blood cell that fights infections and other diseases, become cancerous and affect the skin and blood.